NCT06070506 is a clinical trial in Heart Failure, sponsored by Yihui Kong.

Who is sponsoring NCT06070506?

NCT06070506 is sponsored by Yihui Kong.

What condition does NCT06070506 study?

NCT06070506 studies Heart Failure, Diagnosis.

Is NCT06070506 still recruiting?

NCT06070506 is currently completed. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT06070506

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Heart Failure With Improved Ejection Fraction and Deep Learning

Completed Last updated 11 October 2023

What this trial tests

trial in Heart Failure in 422 participants. Completed in 20 May 2023.

Timeline

1 March 2022

Primary endpoint
31 December 2022

20 May 2023

Quick facts

Lead sponsor	Yihui Kong
Status	Completed
Study type	OBSERVATIONAL
Enrollment	422
Start date	1 March 2022
Primary completion	31 December 2022
Estimated completion	20 May 2023
Sites	1 location across China

Conditions studied

Heart Failure — all drugs for Heart Failure →
Diagnosis — all drugs for Diagnosis →

Sponsor

Yihui Kong

Who can join

18 and older, any sex, with Heart Failure or Diagnosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to design a deep learning-based trained model to assist in HFimpEF diagnosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Deep Learning-Based Prediction Model of Heart Failure with Improved Ejection Fraction
Zhang Y, Pan Y, Zhang Y, Wang Y, et al · · 2023 · DOI 10.1101/2023.10.30.23297807

Verify or expand the search:

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Yihui Kong trials

Trials by the same sponsor.

NCT05892172 — Heart Failure and Sleep Disordered Breathing · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06070506 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yihui Kong
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06070506.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing